Sanofi India Logs Weak Q4; Sequential Improvement: ICICI Securities
Blister packs containing Priadel tablets, produced by Sanofi, sit on a pharmacy counter. (Photographer: Chris Ratcliffe/Bloomberg)

Sanofi India Logs Weak Q4; Sequential Improvement: ICICI Securities

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Securities Report

Sanofi India Ltd.’s Q4 CY20’s performance remained weak during the quarter.

Revenue declined 12.8% YoY to Rs 7.2 billion but sequentially improved by 4.9%. Ebitda margin improved 160 basis points YoY with lower expenses but declined by 480 bps QoQ to 23.2%.

Adjusted profit after tax grew 7.4% to Rs 1.2 billion. As per All Indian Origin Chemists and Distributors data, company reported a YoY growth of 3.8% for the quarter.

In the past few years, the company’s growth and profitability was fuelled by the power brands.

Click on the attachment to read the full report:

ICICI Securities Sanofi Q4CY20 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.